FIGURE 3.

A‐C, Subgroup plot of ratios for the effect of treatment on mean AUC C‐peptide at 13 ± 1 (month 3), 26 ± 2 (month 6) and 52 ± 2 (month 12) weeks from the beginning of treatment. Ratio of geometric means for ladarixin (LDX) versus placebo, with 95% confidence intervals, within subgroups of patients as defined at the baseline. When adjusted for multiple subgroup analyses, there was no significant heterogeneity (test of treatment by subgroup interaction) among subgroups. When considering the subgroup with fasting C‐peptide less than the median value (0.205 nmol/L), the 71% improvement seen with LDX versus control at 26 weeks was nominally significant (P = .033, not adjusted for multiple tests), while it was not significant in the other subgroups or at weeks 13 and 52. Ab, antibody; AUC, area under the curve; GMR, Geometric Mean Ratio